{"id":919201,"date":"2025-12-12T07:04:58","date_gmt":"2025-12-12T12:04:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/systematic-review-and-meta-analysis-confirms-tissuecypher-outperforms-traditional-pathology-or-clinical-factors-alone-to-identify-patients-at-increased-risk-of-developing-esophageal-cancer\/"},"modified":"2025-12-12T07:04:58","modified_gmt":"2025-12-12T12:04:58","slug":"systematic-review-and-meta-analysis-confirms-tissuecypher-outperforms-traditional-pathology-or-clinical-factors-alone-to-identify-patients-at-increased-risk-of-developing-esophageal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/systematic-review-and-meta-analysis-confirms-tissuecypher-outperforms-traditional-pathology-or-clinical-factors-alone-to-identify-patients-at-increased-risk-of-developing-esophageal-cancer\/","title":{"rendered":"Systematic Review and Meta-Analysis Confirms TissueCypher\u00ae Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer"},"content":{"rendered":"

\nAcross multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care
\n<\/h2>\n
\n

FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher\u00ae<\/sup> Barrett\u2019s Esophagus test provides clinically validated risk stratification for patients with Barrett\u2019s esophagus (BE). The findings confirm that TissueCypher can outperform traditional pathology or clinical factors alone to identify patients at increased risk of developing esophageal cancer.<\/p>\n

The paper, titled \u201cThe Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett\u2019s Esophagus: Systematic Review and Meta-Analysis,\u201d was published in the Journal of Clinical Gastroenterology<\/a>. The analysis consolidated data from six previously published studies and found that TissueCypher consistently identifies patients at greater risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), a key step toward enabling personalized, risk-aligned patient management aimed at preventing cancer.<\/p>\n

\u201cOur findings provide strong evidence that TissueCypher delivers meaningful risk stratification for patients with Barrett\u2019s esophagus,\u201d said Caitlin C. Houghton, M.D., board-certified foregut surgeon at Keck Medicine of USC in Los Angeles, California, and lead author of the study. \u201cBy identifying which patients are truly at high risk for progression to esophageal cancer \u2014 and which are not \u2014 TissueCypher can help physicians personalize care, flagging those who may benefit from earlier intervention and providing confidence in continuing routine surveillance for those at low risk.\u201d<\/p>\n

SRMAs represent rigorous, high-quality evidence for clinical validation because they synthesize findings across multiple studies to provide overall estimates of performance. The results of this SRMA represent the most comprehensive validation of the TissueCypher test to date, reinforcing its value as an evidence-based tool for risk stratification in BE. The study demonstrates TissueCypher\u2019s predictive performance across patients with non-dysplastic BE (NDBE), indefinite for dysplasia (IND) and low-grade dysplasia (LGD), and shows that the test outperforms histologic assessment in identifying patients at greatest risk of progression.<\/p>\n

\n Key findings of the SRMA indicate TissueCypher can help physicians:<\/strong>\n <\/p>\n